Back to Search
Start Over
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
- Source :
- The Lancet Haematology; February 2024, Vol. 11 Issue: 2 pe101-e113, 13p
- Publication Year :
- 2024
-
Abstract
- The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple myeloma.
Details
- Language :
- English
- ISSN :
- 23523026
- Volume :
- 11
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- The Lancet Haematology
- Publication Type :
- Periodical
- Accession number :
- ejs65355163
- Full Text :
- https://doi.org/10.1016/S2352-3026(23)00366-6